Skip to main content
. 2015 Jan;36(Suppl 1):S81–S90. doi: 10.1016/j.neurobiolaging.2014.04.035

Table 3.

Estimated sample sizes (95% CI) per arm using whole brain annualized PBVC (80% power at the 5% significance level to detect 25% reduction in disease progression) with and without controlling for normal aging calculated from manual-KN-BSI, STEPS-KN-BSI, pBSI1, pBSIγ, and gBSI for ADNI

Manual-KN-BSI STEPS-KN-BSI pBSI1 pBSIγ gBSI
1.5 T
 Based on AD atrophy rates alone (N = 133) 76 (58–100) 71 (53–96) 68 (51–93) 75 (56–99) 66 (50–90)
 Controlling for normal aging (N = 328) 211 (142–340) 203 (137–327) 185 (125–285) 197 (135–301) 183 (123–284)
3 T
 Based on AD atrophy rates alone (N = 24) 81 (37–162) 82 (40–158) 84 (40–162) 86 (41–171) 82 (40–159)
 Controlling for normal aging (N = 63) 194 (70–854) 179 (72–675) 180 (70–644) 161 (61–573) 179 (69–629)
Comparison Percentage difference of sample size (95% CI), p-value
1.5 T 3T
Manual-KN-BSI versus STEPS-KN-BSI
 AD rates alone −6.6 (−13.4 to 0.6), >0.05 1.4 (−10.9 to 20.1), >0.05
 Controlling for aging −3.8 (−13.2 to 6.4), >0.05 −0.8 (−29.1 to 15.9), >0.05
Manual-KN-BSI versus gBSI
 AD rates alone −12.1 (−18.8 to −5.0), <0.05 −1.7 (−10.8 to 20.6), >0.05
 Controlling for aging −13.3 (−21.6 to −4.2), <0.05 −7.5 (−28.9 to 16.6), >0.05
STEPS-KN-BSI versus gBSI
 AD rates alone −6.5 (−10.6 to −2.3), <0.05 −0.3 (−3.3 to 3.3), >0.05
 Controlling for aging −9.8 (−16.0 to −3.5), <0.05 0.0 (−4.8 to 4.3), >0.05
pBSI1 versus gBSI
 AD rates alone −2.4 (−5.0 to 0.6), >0.05 −3.2 (−6.6 to 1.2), >0.05
 Controlling for aging −1.0 (−4.4 to 3.0), >0.05 −0.6 (−6.5 to 5.2), >0.05
pBSIγ versus gBSI
 AD rates alone −10.7 (−15.2 to −5.8), <0.05 −4.8 (−13.6 to 9.0), >0.05
 Controlling for aging −7.0 (−12.5 to −1.1), <0.05 1.1 (−6.0 to 35.2), >0.05

Key: AD, Alzheimer's disease; ADNI, Alzheimer's Disease Neuroimaging Initiative; BSI, boundary shift integral; CI, confidence interval; gBSI, generalized boundary shift integral; PBVC, percentage brain volume change.